Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00544453 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
A Phase 1 study, sponsored by Molecular NeuroImaging.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00544453 is a Phase 1 study that was terminated before completion, run by Molecular NeuroImaging. The registered enrollment target is 2 participants.
The verdict
NCT00544453, a Phase 1 study, was terminated before completion, sponsored by Molecular NeuroImaging.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-308, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged Alzheimer's (AD) subjects and healthy controls To perform blood metabolite characterization of 123-I MNI-308 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I MNI-308 as a single photon computed tomography (SPECT) brain imaging agent Evaluate the test/retest reproducibility of 123-I MNI-308 and SPECT in AD subjects and healthy control
Interventions
- DRUG [123I] MNI-308
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00544453
The ClinicalTrials.gov registry entry for NCT00544453 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [123I] MNI-308 is the first listed.
NCT00544453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00544453 about?
NCT00544453 is a clinical study titled "Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC". The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-308, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged Alzheimer's (AD) subjects and healthy controls To ...
What is the current status of trial NCT00544453?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00544453?
The interventions under investigation include: [123I] MNI-308 (DRUG).
Who is sponsoring clinical trial NCT00544453?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.